These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9390741)

  • 1. Simultaneous determination of L-dopa and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection.
    Blandini F; Martignoni E; Pacchetti C; Desideri S; Rivellini D; Nappi G
    J Chromatogr B Biomed Sci Appl; 1997 Oct; 700(1-2):278-82. PubMed ID: 9390741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of hydroxyl free radical formation in human platelets using high-performance liquid chromatography with electrochemical detection.
    Blandini F; Martignoni E; Ricotti R; di Jeso F; Nappi G
    J Chromatogr B Biomed Sci Appl; 1999 Sep; 732(1):213-20. PubMed ID: 10517238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous determination of levodopa and 3-O-methyldopa in human plasma by liquid chromatography with electrochemical detection.
    Saxer C; Niina M; Nakashima A; Nagae Y; Masuda N
    J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Apr; 802(2):299-305. PubMed ID: 15018791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease.
    Blandini F; Nappi G; Fancellu R; Mangiagalli A; Samuele A; Riboldazzi G; Calandrella D; Pacchetti C; Bono G; Martignoni E
    J Neural Transm (Vienna); 2003 Aug; 110(8):911-22. PubMed ID: 12898346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa.
    Antonini A; Bondiolotti G; Natuzzi F; Bareggi SR
    Eur Neuropsychopharmacol; 2010 Oct; 20(10):683-7. PubMed ID: 20570113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new HILIC-MS/MS method for the simultaneous analysis of carbidopa, levodopa, and its metabolites in human plasma.
    Vilhena Rde O; Pontes FL; Marson BM; Ribeiro RP; de Carvalho KA; Cardoso MA; Pontarolo R
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Sep; 967():41-9. PubMed ID: 25063927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous determination of levodopa methyl ester, levodopa, 3-O-methyldopa and dopamine in plasma by high-performance liquid chromatography with electrochemical detection.
    Rondelli I; Acerbi D; Mariotti F; Ventura P
    J Chromatogr B Biomed Appl; 1994 Feb; 653(1):17-23. PubMed ID: 8012555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of L-dopa, carbidopa, 3-O-methyldopa and entacapone in human plasma by HPLC-ED.
    Bugamelli F; Marcheselli C; Barba E; Raggi MA
    J Pharm Biomed Anal; 2011 Feb; 54(3):562-7. PubMed ID: 21035976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral markers of oxidative stress in Parkinson's disease. The role of L-DOPA.
    Martignoni E; Blandini F; Godi L; Desideri S; Pacchetti C; Mancini F; Nappi G
    Free Radic Biol Med; 1999 Aug; 27(3-4):428-37. PubMed ID: 10468218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simple automated high-performance liquid chromatographic column-switching technique for the measurement of dopa and 3-O-methyldopa in plasma.
    Zürcher G; Da Prada M
    J Chromatogr; 1990 Sep; 530(2):253-62. PubMed ID: 2127780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved high-performance liquid chromatographic analysis with double detection system for L-dopa, its metabolites and carbidopa in plasma of parkinsonian patients under L-dopa therapy.
    Betto P; Ricciarello G; Giambenedetti M; Lucarelli C; Ruggeri S; Stocchi F
    J Chromatogr; 1988 Dec; 459():341-9. PubMed ID: 3243910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
    Ishihara A; Miyachi T; Nakamura T; Ohtsuki T; Kimura Y; Kihira K; Yamawaki T; Matsumoto M
    Hiroshima J Med Sci; 2011 Sep; 60(3):57-62. PubMed ID: 22053701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease.
    Blandini F; Fancellu R; Martignoni E; Mangiagalli A; Pacchetti C; Samuele A; Nappi G
    Clin Chem; 2001 Jun; 47(6):1102-4. PubMed ID: 11375298
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of 3-O-methyldopa in the side effects of L-dopa.
    Lee ES; Chen H; King J; Charlton C
    Neurochem Res; 2008 Mar; 33(3):401-11. PubMed ID: 17713853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for L-dopa incorporation into cell proteins in patients treated with levodopa.
    Rodgers KJ; Hume PM; Morris JG; Dean RT
    J Neurochem; 2006 Aug; 98(4):1061-7. PubMed ID: 16771833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bound, free, and total L-dopa measurement in plasma of Parkinson's disease patients.
    Müller T; Thiede HM
    J Neural Transm (Vienna); 2019 Nov; 126(11):1417-1420. PubMed ID: 31396704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous measurement of L-dopa, its metabolites and carbidopa in plasma of parkinsonian patients by improved sample pretreatment and high-performance liquid chromatographic determination.
    Lucarelli C; Betto P; Ricciarello G; Giambenedetti M; Corradini C; Stocchi F; Belliardo F
    J Chromatogr; 1990 Jul; 511():167-76. PubMed ID: 2211908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement.
    Tohgi H; Abe T; Yamazaki K; Saheki M; Takahashi S; Tsukamoto Y
    Neurosci Lett; 1995 Jun; 192(3):165-8. PubMed ID: 7566641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.